Kvantitativna analiza aksijalnih dvodimenzionalnih ručno segmentisanih slika dobijenih primenom transrektalnog ultrazvuka u planiranju brahiterapije tumora prostate visokim brzinama doze

Kata Dabić-Stanković; Katarina Rajković; Miodrag Aćimović; Nebojša Milošević; Jovan Stanković

doi:10.2298/VSP150901231D

Kata Dabić-Stanković Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; General Hospital “Medical System Belgrade”, Belgrade, Serbia
Katarina Rajković Institute of Biophysics, Faculty of Medicine, University of Belgrade, Belgrade Serbia
Miodrag Aćimović General Hospital “Medical System Belgrade”, Belgrade, Serbia; Clinic of Urology, Clinical Center of Serbia, Belgrade, Serbia
Nebojša Milošević Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Jovan Stanković General Hospital “Medical System Belgrade”, Belgrade, Serbia; High Medical School, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP150901231D

Ključne reči: prostatic neoplasms||, ||prostata, neoplazme, ultrasonography||, ||ultrasonografija, brachytherapy||, ||brahiterapija, models, theoretical||, ||modeli, teorijski,

Sažetak

Uvod/Cilj. Ocrtavanje kapsule prostate, preplaniranje i procedure primene katetera u brahiterapiji visokim brzinama doze [high-dose rate brachytherapy (HDR-BT)] zasniva se na ručnoj segmentaciji transrektalne ultrazvučne (TRUS) slike. Cilj rada bio je da se korišćenjem dvodimenzionalne TRUS aksijalne slike kvantitativno analizira konzistentnost ocrtavanja kapsule prostate za svaku HDR-BT frakciju, kao i promena oblika kapsule prostate tokom HDR-BT. Metode. Na grupu od 16 bolesnika bila je primenjena definisana HDR-BT u Odeljenju za brahiterapiju privatne opšte bolnice – Medicinski sistem Beograd. Ukupna primenjena srednja doza na metu od 52 Gy bila je podeljena u četiri individualne frakcije i svaka frakcija primenjena sa pauzom od dve do tri nedelje. Aksijalna vizualizacija prostate i ručno segmentisanje pre svake fracije izvedeno je pomoću ultrazvučnog uređaja B-K Medical. Ocrtavanje je vršio isti terapeut. Kvantitativna analiza, analiza površine i oblika prostate bila je primenjena na 2D-TRUS aksijalne slike prostate za svakog bolesnika posebno. Analiza površine koristila se za izračunavanje srednje vrednosti površine poprečnog preseka prostate. Parametri oblika prostate, fraktalna dimenzija i cirkularnost konture kapsule prostate bili su procenjeni na slici najvećeg poprečnog preseka prostate.
Rezultati. Ispitivani uzorak obuhvatio je četiri faze (TRUS prostate pre prve, druge, treće i četvrte HDR-BT frakcije). Statistička analiza pokazala je da u toku HDR-BT frakcije nije bilo značajne razlike u srednjoj vrednosti površine, kao ni u obliku kapsule prostate na njenom najvećem preseku.
Zaključak. Kvantitativna analiza TRUS aksijalne segmetisane slike prostate pokazala je uspešno ocrtavanje prostate u seriji ručno segmentisanih TRUS slika i nepromenjen oblik prostate na najvećem njenom preseku u toku HDR-BT frakcija.

Reference

Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Can-cer J Clin 1999; 49(1): 33−64, 1.

Acimovic M, Dabic-Stankovic K, Pejcic T, Dzamic Z, Rafailovic D, Hadzi-Djokic J. Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recur-rence after radical prostatectomy. J BUON 2013; 18(4): 954−60.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, di-agnosis, and treatment of clinically localised disease. Eur Urol 2011; 59(1): 61−71.

Arsenijević T, Dabić-Stanković K, Aćimović M, Radošević-Jelić LJ. Radiotherapy in Prostate Cancer.In: Spiess P, editor. Prostate Cancer: Diagnostic and Therapeutic Advances. Rijeka, Croatia: InTech; 2011.

Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, et al. Pathological and oncological outcomes of elderly men with clinically localized prostate cancer. Jpn J Clin Oncol 2013; 43(12): 1238−42.

Blasko J, Radge H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using tranrec-tal ultrasound and temlate guidance. Endocuriether Hyper-therm Oncol 1987; 3: 131–9.

Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific an-tigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154(3): 1096−9.

Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Ca-vanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46(4): 839−50.

Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat On-col Biol Phys 2012; 82(5): 1889−96.

Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High-dose-rate monotherapy: safe and effective bra-chytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81(5): 1286−92.

Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer mo-notherapy reduces toxicity compared to low dose rate palla-dium seeds. J Urol 2004; 171(3): 1098−104.

Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, et al. High-dose-rate brachytherapy alone for localized prostate can-cer in patients at moderate or high risk of biochemical recur-rence. Int J Radiat Oncol Biol Phys 2012; 82(4): 1376−84.

Rogers CL, Alder SC, Rogers RL, Hopkins SA, Platt ML, Childs LC, et al. High dose brachytherapy as monotherapy for inter-mediate risk prostate cancer. J Urol 2012; 187(1): 109−16.

Yoshioka Y, Konishi K, Sumida I, Takahashi Y, Isohashi F, Ogata T, et al. Monotherapeutic high-dose-rate brachytherapy for pros-tate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011; 80(2): 469−75.

Das KR. Prostate brachytherapy: HDR or seed implant. J Med Phys 2006; 31(4): 239−41.

Cosset JM, Haie-Meder C. Brachytherapy for prostate cancer: high dose rate or low-dose rate? Cancer Radiother 2005; 9(8): 610−9. (French)

King CR. LDR vs. HDR brachytherapy for localized prostate cancer: The view from radiobiological models. Brachytherapy 2002; 1(4): 219−26.

Kälkner KM, Kubicek G, Nilsson J, Lundell M, Levitt S, Nilsson S, et al. Prostate volume determination: Differential volume mea-surements comparing CT and TRUS. Radiother Oncol 2006; 81(2): 179−83.

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, et al. Prostate volume measurement by transrectal ultrasound and computed tomography before and after per-manent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 60(3): 767−76.

Buch K, Morancy T, Kaplan I, Qureshi MM, Hirsch AE, Rofksy NM, et al. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance im-aging: a feasibility study. J Contemp Brachytherapy 2015; 6(4): 337−43.

Holmes DR 3rd, Davis BJ, Goulet CC, Wilson TM, Mynderse LA, Furutani KM, et al. Shape analysis of the prostate: establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. Brachytherapy 2014; 13(5): 465−70.

Litjens G, Toth R, van de Ven W, Hoeks C, Kerkstra S, Ginneken B, et al. Evaluation of prostate segmentation algorithms for MRI: The PROMISE12 challenge. Med Image Anal 2014; 18(2): 359−73.

Mahdavi SS, Chng N, Spadinger I, Morris WJ, Salcudean SE. Semi-automatic segmentation for prostate interventions. Med Image Anal 2011; 15(2): 226−37.

Pfengfei W, Yiguang L, Yongzhong L, Liping C. TRUS Image seg-mentation driwen by narrow band contrast pattern using shape space embedded level sets. In: Jian Y, Fang F, Changyin S, editors. Intelligent Science and Intelligent Data Engineering: Lecture Notes in Computer Science. Berlin, Heidelberg: Springer-Verlag; 2013. p. 339−46.

Pingkun Y, Sheng X, Baris T, Kruecker J. Discrete deformable model guided by partial active shape model for TRUS image segmentation. IEEE T Biomed Eng 2010; 57(5): 1158−66.

Thompson S, Delaney G, Gabriel G, Izard MA, Hruby G, Ja-gavkar R, et al. Prostate brachytherapy in New South Wales: Patterns of care study and impact of caseload on treatment quality. J Contemp Brachytherapy 2015; 6(4): 344−9.

Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012; 11(1): 20−32.

Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy 2013; 5(1): 33−41.

Milosević NT, Ristanović D, Marić DL, Rajković K. Morphology and cell classification of large neurons in the adult human den-tate nucleus: A quantitative study. Neurosci Lett 2010; 468(1): 59−63.

Ristanović D, Milosević NT, Stefanović BD, Marić DL, Rajković K. Morphology and classification of large neurons in the adult human dentate nucleus: A qualitative and quantitative analysis of 2D images. Neurosci Res 2010; 67(1): 1−7.

Milosević NT, Ristanović D, Jelinek HF, Rajković K. Quantitative analysis of dendritic morphology of the α and δ retinal gan-glion cells in the rat: A cell classification study. J Theor Biol 2009; 259(1): 142−50.

Alder H, Roessler EB. Introduction to Probability and Statistics. San Francisco, USA: WH Freeman and Co; 1972.

Rajković K, Bačić G, Ristanović D, Milošević NT. Mathematical Model of Neuronal Morphology: Prenatal Development of the Human Dentate Nucleus. Biomed Res Int 2014; 2014: 1−8.

Riffenburgh RH. Statistics in Medicine. London, UK: Academic Press; 1999.

Di Ieva A, Grizzi F, Sherif C, Matula C, Tschabitscher M. An-gioarchitectural heterogeneity in human glioblastoma multi-forme: A fractal-based histopathological assessment. Micro-vasc Res 2011; 81(2): 222−30.

Lopes R, Betrouni N. Fractal and multifractal analysis: A review. Med Image Anal 2009; 13(4): 634−49.

Sanguineti G, Marcenaro M, Franzone P, Foppiano F, Vitale V. Neoadjuvant androgen deprivation and prostate gland shrin-kage during conformal radiotherapy. Radiother Oncol 2003; 66(2): 151−7.

Budiharto T, Slagmolen P, Hermans J, Maes F, Verstraete J, Heuvel FV, et al. A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer. Radiother Oncol 2009; 90(3): 331−6.